Biotechnology
In Q2 FY2026, Regeneron generated $4.29B in revenue, up 16.7% YoY, driven by strong Dupixent collaboration revenue and EYLEA HD growth, despite persistent competitive pressures on legacy EYLEA and a 6.8% decline in net income to $1.30B.
Key risk: Revenue Concentration and EYLEA Biosimilar Pressure
Regeneron relies heavily on EYLEA HD, EYLEA, and Dupixent revenues. The loss of market share for legacy EYLEA due to biosimilar entry and compounding alternatives may harm total revenue if EYLEA HD adoption does not fully compensate.
Other Biotechnology companies